Biotech News
Related news
MNKDMannKind2026-06-05 23:35 EST
Data at ADA 2026 Highlights Key Findings from Clinical and Real‑World Studies of MannKind’s Afrezza® (Inhaled Insulin) Across Pediatric Care, Pregnancy, and Use with Automated Insulin Delivery (AID) Systems
MNKDMannKind2026-05-29 16:30 EST
MannKind Announces FDA Approval of Afrezza®, the First and Only Inhaled Mealtime Insulin for Use in Children and Adolescents Aged 6 and Older Living with Diabetes
RYTMRhythm Pharmaceuticals2026-09-22 12:00 EST
Rhythm Pharmaceuticals Announces Health Canada Approval of IMCIVREE® (setmelanotide) for Weight Management in Adult and Pediatric Patients 4 years of Age and Older with Acquired Hypothalamic Obesity
MISTMilestone Pharmaceuticals Inc.2026-09-03 13:35 EST
Milestone Pharmaceuticals Announces NMPA Approval of Etripamil Nasal Spray for PSVT in China, Marking First Regulatory Approval of Etripamil Outside of the United States
VANIVivani Medical2026-06-25 11:30 EST
Vivani Medical Receives Regulatory Approval for the Initiation of SLIM-1, a Phase 1 Clinical Trial of NPM-139 Semaglutide Implant in Obesity and Chronic Weight Management
NAMSNewAmsterdam Pharma2026-09-21 13:00 EST
NewAmsterdam Pharma and Menarini Group Receive European Commission Approval for Ubeslo® (Obicetrapib Monotherapy) and Evlarco® (Obicetrapib Plus Ezetimibe Fixed-Dose Combination)
RYTMRhythm Pharmaceuticals2026-08-24 12:00 EST
Rhythm Pharmaceuticals Announces MHLW Approval of IMCIVREE® (setmelanotide) for Patients with Acquired Hypothalamic Obesity (HO) in Japan
SGMTSagimet Biosciences2026-08-13 11:00 EST
Sagimet Biosciences Receives FDA “Study May Proceed” Letter and IND Clearance for Phase 3 Trial in Acne in Adolescent and Adult Patients
VKTXViking Therapeutics2026-06-11 11:05 EST
Viking Therapeutics Announces Appointment of Hubert C. Chen, M.D., as Chief Medical Officer
MLYSMineralys Therapeutics2026-08-04 12:00 EST
Mineralys Therapeutics to Announce Second Quarter 2026 Financial Results and Host Conference Call on Tuesday, August 11, 2026
MannKind
Inhaled Drug Delivery MannKind develops and commercializes drug-device combinations using Technosphere particles and dry-powder inhalers for rapid, deep-lung delivery. Commercial Portfolio Afrezza is an inhaled mealtime insulin, Tyvaso DPI is manufactured for United Therapeutics, and FUROSCIX provides subcutaneous furosemide for fluid...
Recent company news
MNKDMannKind2026-09-09 10:30 EST
MannKind and Rose Pharma Inc Enter Licensing and Collaboration Agreement to Develop an Inhaled Rapid-Acting, Short-Duration GLP-1 for Weight Management
MNKDMannKind2026-09-09 10:30 EST
MannKind and Rose Pharma Inc Enter Licensing and Collaboration Agreement to Develop an Inhaled Rapid-Acting, Short-Duration GLP-1 for Weight Management
MNKDMannKind2026-09-02 12:30 EST
MannKind to Present at Upcoming Investor Conferences
MNKDMannKind2026-09-02 12:30 EST
MannKind to Present at Upcoming Investor Conferences
MNKDMannKind2026-08-05 20:01 EST
MannKind Reports Second Quarter 2026 Financial Results and Provides Business Update
Stock data
- Close
- 3.71 USD
- Market cap
- 1.06B USD
- Exchange
- NASDAQ
- Sector
- Biopharma
- Location
- United States